Blue Jet Healthcare Ltd (BLUEJET) — shareholding pattern, promoter holding, financials and share price

About Blue Jet Healthcare Ltd (BLUEJET)

Blue Jet Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BLUEJET and on the BSE under scrip code 544009. Its ISIN is INE0KBH01020.

Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India. [1]

Blue Jet Healthcare is a Mumbai‑headquartered specialty pharmaceutical and CDMO company manufacturing contrast media intermediates, high‑intensity sweeteners (saccharin and salts) and pharma intermediates/APIs, operating multiple regulatory‑accredited facilities and providing development, process research, and contract manufacturing solutions to global innovators and generic players.

Q3 FY26 reported revenue of Rs.1,924 mn with EBITDA of Rs.469 mn (24% margin) and PAT of Rs.402 mn, while 9M FY26 revenue is Rs.7,127 mn with EBITDA margin of 31% and PAT margin of 26%; recent quarter saw sharp YoY decline driven by customer de‑stocking and product mix shifts but nine‑month performance remains resilient.

Listed peers in Pharmaceuticals: Shilpa Medicare Ltd, Viyash Scientific Ltd, Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd, Sanofi Consumer Healthcare India Ltd, Strides Pharma Science Ltd.

Valuation & Returns

10 Jul 2026

At ₹623.35 a share on 10 Jul 2026, Blue Jet Healthcare Ltd (BLUEJET) was valued at a price-to-earnings ratio of 47.61x against an industry P/E of 36.41x and a price-to-book of 10.41x on a book value of ₹59.87 per share as of Mar 2025. Solomo computes return on equity of 21.87% and return on capital employed of 29.38% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.

P/E
47.61x
Industry P/E
36.41x
P/B
10.41x
EPS (TTM)
₹13.09
Book value / share
₹59.87
ROE
21.87%
ROCE
29.38%
ROA
17.48%
Debt / equity
0.02x
Dividend yield
0.19%
EBITDA margin
38.29%
52-week range
₹325.2 – ₹1,028.2

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2021

In the year ended Mar 2021, Blue Jet Healthcare Ltd (BLUEJET) reported revenue of ₹499 crore, net profit of ₹136 crore and earnings per share of ₹1,396.49. That compares with revenue of ₹538 crore and net profit of ₹145 crore in Mar 2020. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹235 crore and net profit ₹64 crore (standalone).

Consolidated annual results for Blue Jet Healthcare Ltd (BLUEJET), Mar 2020 to Mar 2021. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2020Mar 2021
Revenue (₹ cr)538499
Net profit (₹ cr)145136
EPS (₹)24,141.671,396.49
Compound annual growth for Blue Jet Healthcare Ltd (BLUEJET). Stock price CAGR is price return and excludes dividends.
Measure5Y3Y1Y
Sales growth13.86%14.65%-7.30%
Profit growth16.10%18.90%-6.33%
Stock price CAGR---39%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 73.15% of Blue Jet Healthcare Ltd (BLUEJET) (down 6.66 pp QoQ), foreign institutional investors (FII) hold 0.62% and domestic institutional investors (DII) hold 9.12%. Market capitalisation was ₹11,799 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2023.

Largest disclosed public shareholders in Jun 2026: Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 3.83%, Shamyak Investment Private Limited 2.87%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202673.15%-0.62%9.12%26.85%
Mar 202679.81%-0.88%4.51%20.19%
Dec 202579.81%-1.14%4.65%20.19%
Sep 202579.81%-1.82%3.63%20.19%
Jun 202586%-1.97%0.94%14%
Mar 202586%-2.29%1.33%14%
Dec 202486%-1.1%2.02%14%
Sep 202486%-2.18%1.74%14%
Every quarter since Dec 2023 Filing data, not investment advice.